한글목차

비호지킨 림프종(NHL) 시장 규모는 최근 현저한 성장을 보이고 있습니다. 2025년 108억 6,000만 달러에서 2026년에는 117억 3,000만 달러에 이르고, CAGR 8.0%로 성장할 전망입니다. 지난 몇 년간의 성장은 전 세계 NHL 발병률 증가, 화학요법 요법의 발전, 의료비 지출 증가, 림프계 암에 대한 인식 증가, 종양학 병원 인프라 확충에 기인하는 것으로 보입니다.

비호지킨 림프종(NHL) 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 164억 4,000만 달러에 이르고, CAGR은 8.8%를 나타낼 전망입니다. 예측 기간의 성장 요인으로는 표적치료제 파이프라인 확대, 생물학적 제제 승인 증가, 맞춤의료 도입 확대, 신흥 시장 접근성 확대, 줄기세포 이식 시술 증가 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 면역요법 및 표적치료제 도입 확대, 병용요법 사용 증가, 조기 및 정확한 진단에 대한 관심 증가, 맞춤 치료 프로토콜 확대, 외래 및 재택 치료 모델로의 전환 등이 있습니다.

비호지킨 림프종의 높은 발병률은 향후 몇 년 동안 비호지킨 림프종 시장의 성장을 견인할 것으로 예측됩니다. 비호지킨 림프종은 인체의 면역 방어에 중요한 역할을 하는 림프계에 기원한 암의 일종입니다. 비호지킨 림프종 유병률은 특정 시점에 해당 질환으로 진단받았거나 앓고 있는 인구 내 환자 수를 나타냅니다. 비호지킨 림프종 치료는 암세포를 표적으로 삼아 조절함으로써 이미 이 질환을 앓고 있는 환자들의 치료 성적을 개선하는 데 기여합니다. 예를 들어, 미국의 암 보건 기관인 미국암협회(American Cancer Society)에 따르면, 2023년 1월 기준 비호지킨 림프종은 전체 암 발생의 약 4%를 차지하며, 2023년에는 미국에서 약 8만 550명(남성 4만 4,880명, 여성 3만 5,670명)이 발병 발생할 것으로 예측됩니다. 또한, 2023년에는 비호지킨 림프종으로 인한 사망자 수가 약 2,180명에 달할 것으로 추정하고 있습니다. 따라서 비호지킨 림프종의 높은 발병률이 비호지킨 림프종 시장 확대에 기여하고 있습니다.

비호지킨 림프종 시장에서 사업을 영위하는 주요 기업들은 경쟁 우위를 강화하기 위해 엡코리타맙-바이스프(EPKINLY)와 같은 첨단 면역치료제 도입에 집중하고 있습니다. 엡코리타맙-bysp(EPKINLY)는 CD20을 발현하는 B세포 악성종양을 표적으로 개발된 임상 단계의 피하주사 면역치료제로, 특히 재발성 또는 난치성 B세포성 비호지킨 림프종 환자에서 임상시험에서 유망한 결과를 보이고 있습니다. 예를 들어, 2023년 11월 미국 제약사 애브비는 미국 식품의약국(FDA)으로부터 에피코리타맙-바이스프(EPKINLY)에 대해 획기적 치료제 지정을 획득했습니다. 이 지정은 두 가지 이상의 이전 치료 후 재발성 또는 난치성 여포성 림프종 성인 환자 치료에 부여된 것입니다. 또한, 유럽의약품청(EMA)은 해당 적응증에 대한 엡코리타맙(TEPKINLY)의 품목허가 신청을 승인했습니다. 이러한 진전은 I/II상 EPCORE NHL-1 임상시험에서 보고된 결과에 의해 뒷받침되고 있습니다. 이 임상시험은 재발성, 진행성 또는 난치성 CD20 양성 성숙 B세포 비호지킨 림프종(여포형 림프종 포함) 성인 환자 128명을 대상으로 에피코리타맙의 피하 투여에 따른 안전성 및 예비 유효성을 평가하였습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Non-Hodgkin lymphoma is a type of cancer affecting the lymphatic system and is marked by the abnormal proliferation of white blood cells. It develops within the immune system component of the body's lymphatic system, which plays a key role in fighting infections.

The primary types of non-Hodgkin lymphoma (NHL) include B-cell lymphoma and T-cell lymphoma. B-cell lymphoma refers to a group of cancers that arise from abnormal B lymphocytes in the immune system. Treatment for B-cell non-Hodgkin lymphoma generally involves a combination of therapies such as chemotherapy, immunotherapy, targeted therapy, radiation therapy, and stem cell transplantation. The range of treatments includes surgery, stem cell transplant, chemotherapy, immunotherapy, targeted therapy, and radiation therapy, which may be administered through different routes, including oral, parenteral, and others. These treatments are distributed through channels such as hospital pharmacies, retail pharmacies, online pharmacies, and others, and are used by various end users including hospitals, homecare facilities, specialty centers, and others.

Tariffs have influenced the non hodgkin lymphoma market by increasing costs associated with imported biologics, active pharmaceutical ingredients, and advanced diagnostic equipment, impacting overall treatment affordability. The effects are most visible in immunotherapy and targeted therapy segments, with asia-pacific and emerging markets facing supply chain delays due to reliance on global manufacturing hubs. In response, pharmaceutical companies are localizing production, strengthening regional supply chains, and optimizing sourcing strategies. These shifts are also encouraging domestic manufacturing and long-term resilience in oncology drug development.

The non hodgkin lymphoma (nhl) market research report is one of a series of new reports from The Business Research Company that provides non hodgkin lymphoma (nhl) market statistics, including non hodgkin lymphoma (nhl) industry global market size, regional shares, competitors with a non hodgkin lymphoma (nhl) market share, detailed non hodgkin lymphoma (nhl) market segments, market trends and opportunities, and any further data you may need to thrive in the non hodgkin lymphoma (nhl) industry. This non hodgkin lymphoma (nhl) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The non hodgkin lymphoma (nhl) market size has grown strongly in recent years. It will grow from $10.86 billion in 2025 to $11.73 billion in 2026 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to rising incidence of nhl globally, advances in chemotherapy regimens, increasing healthcare expenditure, growing awareness of lymphatic cancers, expansion of oncology hospital infrastructure.

The non hodgkin lymphoma (nhl) market size is expected to see strong growth in the next few years. It will grow to $16.44 billion in 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to pipeline growth of targeted therapies, increasing approvals of biologics, rising adoption of personalized medicine, expanding access in emerging markets, growth in stem cell transplant procedures. Major trends in the forecast period include rising adoption of immunotherapy and targeted therapy, increasing use of combination treatment regimens, growing focus on early and accurate diagnosis, expansion of personalized treatment protocols, shift toward outpatient and home-based care models.

The high prevalence of non-Hodgkin lymphoma is anticipated to drive the growth of the non-Hodgkin lymphoma market in the coming years. Non-Hodgkin lymphoma is a type of cancer that originates in the lymphatic system, which plays a key role in the body's immune defense. The prevalence of non-Hodgkin lymphoma indicates the number of people within a population who are currently diagnosed with or living with the disease at a given point in time. Treatment for non-Hodgkin lymphoma helps improve outcomes for individuals already affected by the condition by targeting and controlling cancerous cells. For example, in January 2023, according to the American Cancer Society, a US-based cancer health organization, non-Hodgkin lymphoma represents about 4% of all cancers and was expected to affect approximately 80,550 individuals in the United States in 2023, including 44,880 males and 35,670 females. The organization also estimated that around 20,180 deaths would occur in 2023 due to non-Hodgkin lymphoma. Therefore, the high prevalence of non-Hodgkin lymphoma is contributing to the expansion of the non-Hodgkin lymphoma market.

Key companies operating in the non-Hodgkin lymphoma market are increasingly concentrating on the introduction of advanced immunotherapies, such as Epcoritamab-bysp (EPKINLY), to strengthen their competitive position. Epcoritamab-bysp (EPKINLY) is an investigational subcutaneous immunotherapy developed to target CD20-expressing B-cell malignancies and has demonstrated encouraging outcomes in clinical trials, particularly in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. For instance, in November 2023, AbbVie Inc., a US-based pharmaceutical company, received a breakthrough therapy designation from the United States Food and Drug Administration for Epcoritamab-bysp (EPKINLY). This designation was granted for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more prior therapies. In addition, the European Medicines Agency validated a Type II application for epcoritamab (TEPKINLY) for the same indication. These developments were supported by previously reported results from the Phase 1/2 EPCORE NHL-1 clinical trial, which assessed the safety and preliminary efficacy of subcutaneous epcoritamab in 128 adult patients with relapsed, progressive, or refractory CD20-positive mature B-cell non-Hodgkin lymphoma, including follicular lymphoma.

In May 2023, Janssen Biotech Inc., a US-based developer of innovative pharmaceutical therapies, entered into a global collaboration and licensing agreement with Cellular Biomedicine Group involving an upfront payment of $245 million. Through this partnership, Janssen seeks to broaden its oncology portfolio and accelerate the development of next-generation chimeric antigen receptor T-cell therapies targeting CD19 and CD20 for relapsed or refractory B-cell malignancies, including diffuse large B-cell lymphoma, which is a major subtype of non-Hodgkin lymphoma. Cellular Biomedicine Group is a US-based biotechnology company focused on advanced cell therapies, including autologous CAR-T candidates that have demonstrated early-stage clinical activity in non-Hodgkin lymphoma.

Major companies operating in the non hodgkin lymphoma (nhl) market are Bayer AG, Teva Pharmaceutical Industries Ltd., F. Hoffmann La Roche Ltd., Merck & Co. Inc., Eli Lilly and Co., Novartis AG, GlaxoSmithKline plc, AbbVie Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Bristol Myers Squibb Co., Pfizer Inc., Celgene Corporation, Sanofi S.A., Janssen Pharmaceuticals Inc., Johnson & Johnson, Boehringer Ingelheim GmbH, Eisai Co. Ltd., Gilead Sciences, Incyte Corporation, Karyopharm Therapeutics, Kite Pharma Inc., Kyowa Hakko Kirin Co. Ltd., MorphoSys AG, Nordic Nanovector ASA, Ono Pharmaceutical Co. Ltd., Seattle Genetics Inc., Spectrum Pharmaceuticals Inc.

North America was the largest region in the non-Hodgkin lymphoma (NHL) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global non-Hodgkin lymphoma (NHL) market report during the forecast period. The regions covered in the non hodgkin lymphoma (nhl) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the non hodgkin lymphoma (nhl) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-Hodgkin lymphoma market includes revenues earned by entities by treating aggressive lymphomas, indolent lymphomas, Burkitt lymphoma, lymphoma and leukemia, and B-cell lymphomas. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Non Hodgkin Lymphoma (NHL) Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses non hodgkin lymphoma (nhl) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for non hodgkin lymphoma (nhl) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The non hodgkin lymphoma (nhl) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: B-Cell Lymphoma; T-Cell Lymphoma
• 2) By Treatment: Surgery; Stem Cell Transplant; Chemotherapy; Immunotherapy; Targeted Therapy; Radiation Therapy
• 3) By Route of Administration: Oral; Parenteral; Other Routes of Administration
• 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
• 5) By End-Users: Hospitals; Homecare; Specialty Centers; Other End Users
• Subsegments:
• 1) By B-Cell Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL); Follicular Lymphoma; Chronic Lymphocytic Leukemia (CLL); Mantle Cell Lymphoma; Burkitt Lymphoma; Marginal Zone Lymphoma; Primary Mediastinal B-Cell Lymphoma
• 2) By T-Cell Lymphoma: Peripheral T-Cell Lymphoma (PTCL); Anaplastic Large Cell Lymphoma (ALCL); Cutaneous T-Cell Lymphoma (CTCL); T-Cell Lymphoblastic Lymphoma; Adult T-Cell Leukemia/Lymphoma (ATLL)
• Companies Mentioned: Bayer AG; Teva Pharmaceutical Industries Ltd.; F. Hoffmann La Roche Ltd.; Merck & Co. Inc.; Eli Lilly and Co.; Novartis AG; GlaxoSmithKline plc; AbbVie Inc.; AstraZeneca plc; Takeda Pharmaceutical Company Limited; Bristol Myers Squibb Co.; Pfizer Inc.; Celgene Corporation; Sanofi S.A.; Janssen Pharmaceuticals Inc.; Johnson & Johnson; Boehringer Ingelheim GmbH; Eisai Co. Ltd.; Gilead Sciences; Incyte Corporation; Karyopharm Therapeutics; Kite Pharma Inc.; Kyowa Hakko Kirin Co. Ltd.; MorphoSys AG; Nordic Nanovector ASA; Ono Pharmaceutical Co. Ltd.; Seattle Genetics Inc.; Spectrum Pharmaceuticals Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Non Hodgkin Lymphoma (NHL) Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Non Hodgkin Lymphoma (NHL) Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Non Hodgkin Lymphoma (NHL) Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Non Hodgkin Lymphoma (NHL) Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Sustainability, Climate Tech & Circular Economy
  • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Rising Adoption Of Immunotherapy And Targeted Therapy
  • 4.2.2 Increasing Use Of Combination Treatment Regimens
  • 4.2.3 Growing Focus On Early And Accurate Diagnosis
  • 4.2.4 Expansion Of Personalized Treatment Protocols
  • 4.2.5 Shift Toward Outpatient And Home-Based Care Models

5. Non Hodgkin Lymphoma (NHL) Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Specialty Centers
• 5.3 Homecare
• 5.4 Oncology Clinics
• 5.5 Research And Academic Institutes

6. Non Hodgkin Lymphoma (NHL) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Non Hodgkin Lymphoma (NHL) Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Non Hodgkin Lymphoma (NHL) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Non Hodgkin Lymphoma (NHL) Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Non Hodgkin Lymphoma (NHL) Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Non Hodgkin Lymphoma (NHL) Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Non Hodgkin Lymphoma (NHL) Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Non Hodgkin Lymphoma (NHL) Market Segmentation

• 9.1. Global Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• B-Cell Lymphoma, T-Cell Lymphoma
• 9.2. Global Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Surgery, Stem Cell Transplant, Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy
• 9.3. Global Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral, Parenteral, Other Routes of Administration
• 9.4. Global Non Hodgkin Lymphoma (NHL) Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
• 9.5. Global Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Homecare, Specialty Centers, Other End Users
• 9.6. Global Non Hodgkin Lymphoma (NHL) Market, Sub-Segmentation Of B-Cell Lymphoma, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma, Burkitt Lymphoma, Marginal Zone Lymphoma, Primary Mediastinal B-Cell Lymphoma
• 9.7. Global Non Hodgkin Lymphoma (NHL) Market, Sub-Segmentation Of T-Cell Lymphoma, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Peripheral T-Cell Lymphoma (PTCL), Anaplastic Large Cell Lymphoma (ALCL), Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoblastic Lymphoma, Adult T-Cell Leukemia/Lymphoma (ATLL)

10. Non Hodgkin Lymphoma (NHL) Market Regional And Country Analysis

• 10.1. Global Non Hodgkin Lymphoma (NHL) Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Non Hodgkin Lymphoma (NHL) Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Non Hodgkin Lymphoma (NHL) Market

• 11.1. Asia-Pacific Non Hodgkin Lymphoma (NHL) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Non Hodgkin Lymphoma (NHL) Market

• 12.1. China Non Hodgkin Lymphoma (NHL) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Non Hodgkin Lymphoma (NHL) Market

• 13.1. India Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Non Hodgkin Lymphoma (NHL) Market

• 14.1. Japan Non Hodgkin Lymphoma (NHL) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Non Hodgkin Lymphoma (NHL) Market

• 15.1. Australia Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Non Hodgkin Lymphoma (NHL) Market

• 16.1. Indonesia Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Non Hodgkin Lymphoma (NHL) Market

• 17.1. South Korea Non Hodgkin Lymphoma (NHL) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Non Hodgkin Lymphoma (NHL) Market

• 18.1. Taiwan Non Hodgkin Lymphoma (NHL) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Non Hodgkin Lymphoma (NHL) Market

• 19.1. South East Asia Non Hodgkin Lymphoma (NHL) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Non Hodgkin Lymphoma (NHL) Market

• 20.1. Western Europe Non Hodgkin Lymphoma (NHL) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Non Hodgkin Lymphoma (NHL) Market

• 21.1. UK Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Non Hodgkin Lymphoma (NHL) Market

• 22.1. Germany Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Non Hodgkin Lymphoma (NHL) Market

• 23.1. France Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Non Hodgkin Lymphoma (NHL) Market

• 24.1. Italy Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Non Hodgkin Lymphoma (NHL) Market

• 25.1. Spain Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Non Hodgkin Lymphoma (NHL) Market

• 26.1. Eastern Europe Non Hodgkin Lymphoma (NHL) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Non Hodgkin Lymphoma (NHL) Market

• 27.1. Russia Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Non Hodgkin Lymphoma (NHL) Market

• 28.1. North America Non Hodgkin Lymphoma (NHL) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Non Hodgkin Lymphoma (NHL) Market

• 29.1. USA Non Hodgkin Lymphoma (NHL) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Non Hodgkin Lymphoma (NHL) Market

• 30.1. Canada Non Hodgkin Lymphoma (NHL) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Non Hodgkin Lymphoma (NHL) Market

• 31.1. South America Non Hodgkin Lymphoma (NHL) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Non Hodgkin Lymphoma (NHL) Market

• 32.1. Brazil Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Non Hodgkin Lymphoma (NHL) Market

• 33.1. Middle East Non Hodgkin Lymphoma (NHL) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Non Hodgkin Lymphoma (NHL) Market

• 34.1. Africa Non Hodgkin Lymphoma (NHL) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Segmentation By Treatment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Non Hodgkin Lymphoma (NHL) Market Regulatory and Investment Landscape

36. Non Hodgkin Lymphoma (NHL) Market Competitive Landscape And Company Profiles

• 36.1. Non Hodgkin Lymphoma (NHL) Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Non Hodgkin Lymphoma (NHL) Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Non Hodgkin Lymphoma (NHL) Market Company Profiles
  • 36.3.1. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. F. Hoffmann La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Eli Lilly and Co. Overview, Products and Services, Strategy and Financial Analysis

37. Non Hodgkin Lymphoma (NHL) Market Other Major And Innovative Companies

• Novartis AG, GlaxoSmithKline plc, AbbVie Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Bristol Myers Squibb Co., Pfizer Inc., Celgene Corporation, Sanofi S.A., Janssen Pharmaceuticals Inc., Johnson & Johnson, Boehringer Ingelheim GmbH, Eisai Co. Ltd., Gilead Sciences, Incyte Corporation

38. Global Non Hodgkin Lymphoma (NHL) Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Non Hodgkin Lymphoma (NHL) Market

40. Non Hodgkin Lymphoma (NHL) Market High Potential Countries, Segments and Strategies

• 40.1 Non Hodgkin Lymphoma (NHL) Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Non Hodgkin Lymphoma (NHL) Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Non Hodgkin Lymphoma (NHL) Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer